MELISSA PENNINGTON: Open Payments
NPI 1225149685 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$354 in 17 payments from 12 companies in 2025. Trend: 2023 $151 · 2024 $200 · 2025 $354
Food & beverage: $354
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 3 | $82 |
| ABBVIE INC. | 3 | $73 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| AstraZeneca Pharmaceuticals LP | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $15 |
Products named: LEQVIO, REXULTI, LINZESS, QULIPTA, FARXIGA, VOWST, Leqembi, GEMTESA.
Industry payments across MO — which companies pay providers there.
